BioXcel Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
BioXcel Therapeutics, Inc. (BTAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-13
- BioXcel Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- BioXcel Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- BioXcel Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month |
|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-15 | ||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-15 | ||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |